Gout therapeutics and drug delivery

Xiuju Peng, Xiaotong Li, Bing Xie, Yaoyao Lai, Alejandro Sosnik, Hamza Boucetta, Zhongjian Chen, Wei He

Research output: Contribution to journalReview articlepeer-review


Gout is a common inflammatory arthritis caused by persistently elevated uric acid levels. With the improvement of people's living standards, the consumption of processed food and the widespread use of drugs that induce elevated uric acid, gout rates are increasing, seriously affecting the human quality of life, and becoming a burden to health systems worldwide. Since the pathological mechanism of gout has been elucidated, there are relatively effective drug treatments in clinical practice. However, due to (bio)pharmaceutical shortcomings of these drugs, such as poor chemical stability and limited ability to target the pathophysiological pathways, traditional drug treatment strategies show low efficacy and safety. In this scenario, drug delivery systems (DDS) design that overcome these drawbacks is urgently called for. In this review, we initially describe the pathological features, the therapeutic targets, and the drugs currently in clinical use and under investigation to treat gout. We also comprehensively summarize recent research efforts utilizing lipid, polymeric and inorganic carriers to develop advanced DDS for improved gout management and therapy.

Original languageEnglish
Pages (from-to)728-754
Number of pages27
JournalJournal of Controlled Release
StatePublished - Oct 2023


  • Advanced therapeutics
  • Drug delivery systems
  • Gout
  • Hyperuricemia
  • Inorganic carriers
  • Lipid carriers
  • Nanoparticles
  • Polymeric carriers

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Gout therapeutics and drug delivery'. Together they form a unique fingerprint.

Cite this